Clinical Trial Results:
A Phase I/II, Ascending, Multi-Dose Study of BMS-663513, An Agonistic Anti-CD137
Monoclonal Antibody, Administered Every Three Weeks to Patients with Metastatic or
Locally Advanced Solid Malignancies.
Revised Protocol Number 07, incorporating Amendments 01, 02, 03, 04, 05, 06, 07 and Administrative Letter Dated 10-Mar-2006.
Summary
|
|
EudraCT number |
2007-000416-91 |
Trial protocol |
FR |
Global completion date |
30 Dec 2008
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
07 Dec 2016
|
First version publication date |
07 Dec 2016
|
Other versions |
|
Summary report(s) |
CA186-001_Synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.